Market Cap (In JPY)
8.99 Billion
Revenue (In JPY)
100.4 Million
Net Income (In JPY)
-1.1 Billion
Avg. Volume
4.45 Million
- Currency
- JPY
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 291.0-876.0
- PE
- -
- EPS
- -
- Beta Value
- 0.702
- ISIN
- JP3836800007
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Mr. Takuya Yokokawa
- Employee Count
- -
- Website
- https://www.ppmx.com
- Ipo Date
- 2021-06-22
- Details
- Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell; and PPMX-T004, an antibody drug conjugate. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.
More Stocks
-
6583
-
JGCCYJGC Holdings Corporation
JGCCY
-
0LD9
-
STAG
-
BIPC
-
MACIW
-
SKTP
-
LRS